Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
10 August 2021Website:
http://www.eliemtx.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Wed, 03 Jul 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
ELYM Latest News
Results from Eliem Therapeutics, Inc.'s phase 1b study, using TNT119 for the treatment of patients with membranous nephropathy, expected by the end of 2024. It is expected that the global membranous nephropathy treatment market could reach $328.4 million by 2034. Two other large market indications that can be targeted using TNT119 are systemic lupus erythematosus and immune thrombocytopenia.
SEATTLE and CAMBRIDGE, United Kingdom, June 28, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), announced today that the Company will be included in the Russell 2000® Index and the broad-market Russell 3000® Index, as part of the annual reconstitution of the Russell stock indexes, effective today.
Eliem to focus on advancing TNT119, an anti-CD19 antibody designed to treat a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia and membranous nephropathy
Eliem (ELYM) announces its decision to halt its Kv7 development program in its quest to explore strategic alternatives. The stock of the company rises 6% in response on Thursday.
Eliem Therapeutics (NASDAQ: ELYM ) stock is taking off on Thursday after the biotechnology company announced plans to explore strategic alternatives. Eliem Therapeutics came to this decision after completing a review of the company and its various programs.
Eliem Therapeutics Inc.'s stock ELYM, -4.76% soared 21% in premarket trade Thursday, after the biotech, which specializes in therapies for neuronal excitability disorders, said it is exploring its strategic options. The Seattle and Cambridge, U.K.-based company said it has halted the development of its Kv7 program, which was focused on treatments for pain and epilepsy.
What type of business is Eliem Therapeutics?
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial. The company also develops preclinical pipeline programs, such as Kv7 Program for pain, epilepsy, and depression; and Anxiolytic for the treatment of generalized anxiety disorder. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington.
What sector is Eliem Therapeutics in?
Eliem Therapeutics is in the Healthcare sector
What industry is Eliem Therapeutics in?
Eliem Therapeutics is in the Biotechnology industry
What country is Eliem Therapeutics from?
Eliem Therapeutics is headquartered in United States
When did Eliem Therapeutics go public?
Eliem Therapeutics initial public offering (IPO) was on 10 August 2021
What is Eliem Therapeutics website?
https://www.eliemtx.com
Is Eliem Therapeutics in the S&P 500?
No, Eliem Therapeutics is not included in the S&P 500 index
Is Eliem Therapeutics in the NASDAQ 100?
No, Eliem Therapeutics is not included in the NASDAQ 100 index
Is Eliem Therapeutics in the Dow Jones?
No, Eliem Therapeutics is not included in the Dow Jones index
When does Eliem Therapeutics report earnings?
The next expected earnings date for Eliem Therapeutics is 09 August 2024